VistaGen Therapeutics, Inc. Aktie News

LOS ANGELES, Feb. 5, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  Vistagen Therapeutics, Inc. ("Vistagen " or "the Company") (NASDAQ: VTGN ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of VTGN durin...

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 12, 2026, at 2:00 p.m. Pacific Time (5:00 p.m. E...

NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline. So what: If you purchased Vistagen common stock during the Class Period you ...

LOS ANGELES, Feb. 2, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  Vistagen Therapeutics, Inc. ("Vistagen " or "the Company") (NASDAQ: VTGN ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of VTGN durin...

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Vistagen between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1...

LOS ANGELES, Jan. 29, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against  Vistagen Therapeutics, Inc. ("Vistagen " or "the Company") (NASDAQ: VTGN ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of VTGN durin...